Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8

Mami Noda, Daichi Tomonaga, Kota Kitazono, Yusaku Yoshioka, Jiadai Liu, Jean Philippe Rousseau, Richard Kinkead, Michael R. Ruff, Candace B. Pert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chemokine signaling is important in neuropathic pain, with microglial cells expressing chemokine (C-C motif) receptor CCR2, CCR5 and CCR8, all playing key roles. In the previous report (Padi et al., 2012), oral administration of a short peptide, RAP-103, for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia after partial ligation of the sciatic nerve in rodents. As for the mechanism of the inhibiting effect of RAP-103, it was speculated to be due to dual blockade of CCR2 and CCR5. We report here that RAP-103 exhibits stronger antagonism for CCR8 (half maximal inhibitory concentration [IC50] 7.7 fM) compared to CCR5 (IC50 < 100 pM) in chemotaxis using primary cultured mouse microglia. In addition, RAP-103 at a concentration of 0.1 pM completely inhibits membrane ruffling and phagocytosis induced by chemokine (C-C motif) ligand 1 (CCL1), an agonist for CCR8. It has been shown that CCL1/CCR8 signaling is important in tactile allodynia induced by nerve ligation. Therefore, CCR8, among other chemokine receptors such as CCR2/CCR5, could be the most potent target for RAP-103. Inhibitory effects of RAP-103 on plural chemokine receptors may play important roles for broad clinical use in neuropathic pain treatment.

Original languageEnglish
Pages (from-to)184-189
Number of pages6
JournalNeurochemistry International
Volume119
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Neuralgia
Ligands
Hyperalgesia
Chemokine Receptors
Inhibitory Concentration 50
Ligation
CCR Receptors
CC Chemokines
Microglia
Sciatic Nerve
Chemotaxis
Phagocytosis
Chemokines
Oral Administration
RAP-103
Rodentia
Peptides
Membranes

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Noda, M., Tomonaga, D., Kitazono, K., Yoshioka, Y., Liu, J., Rousseau, J. P., ... Pert, C. B. (2018). Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochemistry International, 119, 184-189. https://doi.org/10.1016/j.neuint.2017.12.005

Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. / Noda, Mami; Tomonaga, Daichi; Kitazono, Kota; Yoshioka, Yusaku; Liu, Jiadai; Rousseau, Jean Philippe; Kinkead, Richard; Ruff, Michael R.; Pert, Candace B.

In: Neurochemistry International, Vol. 119, 01.10.2018, p. 184-189.

Research output: Contribution to journalArticle

Noda, M, Tomonaga, D, Kitazono, K, Yoshioka, Y, Liu, J, Rousseau, JP, Kinkead, R, Ruff, MR & Pert, CB 2018, 'Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8', Neurochemistry International, vol. 119, pp. 184-189. https://doi.org/10.1016/j.neuint.2017.12.005
Noda, Mami ; Tomonaga, Daichi ; Kitazono, Kota ; Yoshioka, Yusaku ; Liu, Jiadai ; Rousseau, Jean Philippe ; Kinkead, Richard ; Ruff, Michael R. ; Pert, Candace B. / Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. In: Neurochemistry International. 2018 ; Vol. 119. pp. 184-189.
@article{acf9a4eec07746eea25b44914cc8b1a6,
title = "Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8",
abstract = "Chemokine signaling is important in neuropathic pain, with microglial cells expressing chemokine (C-C motif) receptor CCR2, CCR5 and CCR8, all playing key roles. In the previous report (Padi et al., 2012), oral administration of a short peptide, RAP-103, for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia after partial ligation of the sciatic nerve in rodents. As for the mechanism of the inhibiting effect of RAP-103, it was speculated to be due to dual blockade of CCR2 and CCR5. We report here that RAP-103 exhibits stronger antagonism for CCR8 (half maximal inhibitory concentration [IC50] 7.7 fM) compared to CCR5 (IC50 < 100 pM) in chemotaxis using primary cultured mouse microglia. In addition, RAP-103 at a concentration of 0.1 pM completely inhibits membrane ruffling and phagocytosis induced by chemokine (C-C motif) ligand 1 (CCL1), an agonist for CCR8. It has been shown that CCL1/CCR8 signaling is important in tactile allodynia induced by nerve ligation. Therefore, CCR8, among other chemokine receptors such as CCR2/CCR5, could be the most potent target for RAP-103. Inhibitory effects of RAP-103 on plural chemokine receptors may play important roles for broad clinical use in neuropathic pain treatment.",
author = "Mami Noda and Daichi Tomonaga and Kota Kitazono and Yusaku Yoshioka and Jiadai Liu and Rousseau, {Jean Philippe} and Richard Kinkead and Ruff, {Michael R.} and Pert, {Candace B.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.neuint.2017.12.005",
language = "English",
volume = "119",
pages = "184--189",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8

AU - Noda, Mami

AU - Tomonaga, Daichi

AU - Kitazono, Kota

AU - Yoshioka, Yusaku

AU - Liu, Jiadai

AU - Rousseau, Jean Philippe

AU - Kinkead, Richard

AU - Ruff, Michael R.

AU - Pert, Candace B.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Chemokine signaling is important in neuropathic pain, with microglial cells expressing chemokine (C-C motif) receptor CCR2, CCR5 and CCR8, all playing key roles. In the previous report (Padi et al., 2012), oral administration of a short peptide, RAP-103, for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia after partial ligation of the sciatic nerve in rodents. As for the mechanism of the inhibiting effect of RAP-103, it was speculated to be due to dual blockade of CCR2 and CCR5. We report here that RAP-103 exhibits stronger antagonism for CCR8 (half maximal inhibitory concentration [IC50] 7.7 fM) compared to CCR5 (IC50 < 100 pM) in chemotaxis using primary cultured mouse microglia. In addition, RAP-103 at a concentration of 0.1 pM completely inhibits membrane ruffling and phagocytosis induced by chemokine (C-C motif) ligand 1 (CCL1), an agonist for CCR8. It has been shown that CCL1/CCR8 signaling is important in tactile allodynia induced by nerve ligation. Therefore, CCR8, among other chemokine receptors such as CCR2/CCR5, could be the most potent target for RAP-103. Inhibitory effects of RAP-103 on plural chemokine receptors may play important roles for broad clinical use in neuropathic pain treatment.

AB - Chemokine signaling is important in neuropathic pain, with microglial cells expressing chemokine (C-C motif) receptor CCR2, CCR5 and CCR8, all playing key roles. In the previous report (Padi et al., 2012), oral administration of a short peptide, RAP-103, for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia after partial ligation of the sciatic nerve in rodents. As for the mechanism of the inhibiting effect of RAP-103, it was speculated to be due to dual blockade of CCR2 and CCR5. We report here that RAP-103 exhibits stronger antagonism for CCR8 (half maximal inhibitory concentration [IC50] 7.7 fM) compared to CCR5 (IC50 < 100 pM) in chemotaxis using primary cultured mouse microglia. In addition, RAP-103 at a concentration of 0.1 pM completely inhibits membrane ruffling and phagocytosis induced by chemokine (C-C motif) ligand 1 (CCL1), an agonist for CCR8. It has been shown that CCL1/CCR8 signaling is important in tactile allodynia induced by nerve ligation. Therefore, CCR8, among other chemokine receptors such as CCR2/CCR5, could be the most potent target for RAP-103. Inhibitory effects of RAP-103 on plural chemokine receptors may play important roles for broad clinical use in neuropathic pain treatment.

UR - http://www.scopus.com/inward/record.url?scp=85038822506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038822506&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2017.12.005

DO - 10.1016/j.neuint.2017.12.005

M3 - Article

C2 - 29248693

AN - SCOPUS:85038822506

VL - 119

SP - 184

EP - 189

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

ER -